Advances in Portable Transcranial Magnetic Stimulation (TMS): Mechanism, Applications, and Global Validation
Introduction
Transcranial Magnetic Stimulation ( TMS ) is a non-invasive neuromodulation technique that relies on electromagnetic induction to modulate neural activity. Recent advances have introduced portable, low-intensity TMS devices, which offer greater safety and accessibility at the cost of slightly reduced efficacy. This paper presents the principles of TMS, its validated applications, and the benefits of next-generation wearable devices. The availability of CE-certified TMS equipment ensures safety compliance and quality in both clinical and home-use settings.
Mechanism of Action
TMS operates based on Faraday's Law of electromagnetic induction: an alternating magnetic field generated by a coil induces an electric current in the targeted region of the brain. This current modulates neuronal membrane potentials, thereby stimulating or blocking synaptic activity depending on the stimulation parameters: · High-frequency stimulation (≥5 Hz): Enhances cortical excitability, for example, in the treatment of depression. · Low-frequency stimulation (≤1 Hz): Blocks overly active neural networks, such as those involved in migraines.
The plasticity of TMS effects is frequency-dependent, providing the foundation for its treatment flexibility.
Clinical Validation
Internationally, Transcranial Magnetic Stimulation has been recognized as a valid treatment for several conditions: Major Depressive Disorder (MDD): · Approved by the FDA since 2008 for patients with treatment-resistant depression.
· A 1997 placebo-controlled trial demonstrated that daily left prefrontal stimulation resulted in a 5-point decrease on the Hamilton Depression Scale. Migraine:
· Approved by the FDA for pain relief; it modulates cortical excitability related to aura and pain circuits. Obsessive-Compulsive Disorder (OCD):
· Approved in 2018; it corrects aberrant prefrontal-limbic circuits. Schizophrenia (Auditory Hallucinations):
· Recent randomized controlled trials (RCTs) show remarkable symptom reduction using image-guided protocols.
New applications are emerging in Parkinson's disease, stroke recovery, and cognitive impairment.
Target Populations
· Treatment-resistant adults: Ideal candidates for depression and OCD. · Geriatric and pediatric patients: Evidence of safety is increasing for both groups.
· Contraindications: Individuals with implanted metal hardware (e.g., pacemakers) or a history of epilepsy should avoid TMS.
Global Efficacy and Safety Validation
· FDA Approvals: MDD (2008), migraines (2013), OCD (2018). · Clinical Trials: Meta-analyses validate depression response rates of 50–60%, significantly higher than placebo responses.
· Safety Profile: Side effects are mild (e.g., brief headaches, scalp soreness); the risk of seizures is less than 0.1% with prudent use.
Manufacturers now provide TMS/RTMS machine factory wholesale price options, making this advanced therapy more affordable for clinics worldwide.
Portable TMS Devices: Redefining Access
Researchers have developed a wearable repetitive TMS (rTMS) device (3 kg, battery-operated) that delivers 10% of the energy of regular devices but achieves similar therapeutic amplitudes. Key advantages include: Precise Weak Magnetic Fields: Optimized coil geometries deliver therapeutic stimulation at reduced intensities (e.g., 3–18 mT) with minimal discomfort. Home and Community Application: Enables high-frequency modulation during daily activities (e.g., walking), enhancing convenience beyond clinical settings. Closed-Loop Integration: Future devices may integrate with real-time brain signal monitoring for personalized treatment.
Benefits Over Current Therapies
· Drug-Free and Non-invasive: Avoids systemic side effects associated with antidepressants.
· Minimum Downtime: Sessions last 20–40 minutes, allowing immediate resumption of activities.
· Personalizable Protocols: Parameters (intensity, frequency) can be tailored to individual motor thresholds and symptoms.
Conclusion
Portable TMS represents a neuromodulation innovation that combines decades of clinical evidence with cutting-edge engineering. Its low-field technology, consistent efficacy across neuropsychiatric disorders, and minimal side effects make it a promising option for decentralized mental health treatment. Further research will optimize stimulation parameters and expand applications, solidifying its role in modern medicine. As global demand increases, sourcing reliable CE-certified TMS equipment and leveraging TMS/rTMS machine factory wholesale price options will be essential in expanding accessibility and affordability.
References
Integrated from peer-reviewed trials, FDA guidelines, and advancements in device technology.
Transcranial Magnetic Stimulation
Contact information:
WhatsApp: +44 7410558633
Email address : lianlianzhng@gmail.com
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
36 minutes ago
- Associated Press
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chief Financial Officer (CFO) and interim CEO, will continue serving as CFO and as a member of the Board of Directors. 'We are very pleased to welcome Bob to the executive leadership team as we continue to execute on our path forward. Bob's experience, track record and deep understanding of the biopharmaceutical industry will be invaluable as we scale as a commercial entity. With our launch in Europe underway and potential U.S. Food and Drug Administration (FDA) approval in the coming months, we believe this appointment is timely and positions us to drive value for our stakeholders,' commented Faisal G. Sukhtian, Chairman of the Outlook Therapeutics Board of Directors. Mr. Jahr brings more than 20 years of experience in the biopharmaceutical industry building and leading commercial teams spanning therapeutic areas including rare disease, oncology, hematology, autoimmunology, neuroscience, cardiovascular and inflammation. Over the course of his career, he has led operational and commercial efforts for multiple billion dollar assets and franchises. 'LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) has the potential to truly transform the global retina market and offer a much-needed ophthalmic formulation of bevacizumab for wet AMD,' added Mr. Jahr. 'With the commercial launch underway in Europe and potential FDA approval in the U.S. in the near term, I am excited to join the team at such a pivotal time for Outlook Therapeutics. I look forward to adding the depth and breadth of my experience to Outlook Therapeutics and continue building momentum to position it as a leader in the ophthalmology market.' Mr. Jahr joins Outlook Therapeutics having most recently served as the Chief Commercial Officer for Sobi North America (NA), where he oversaw commercial strategy, planning and execution excellence, which includes accountability for all marketing, sales, operations and market access activities. During his tenure at Sobi NA, Mr. Jahr led the immunology and hematology franchises, and three global development asset teams focused on preparing for regulatory submission, life cycle management and launch. Prior to his role at Sobi NA he served as General Manager & Vice President Head of International Markets at UCB Pharma SA (UCB) where he managed the company's portfolio in markets including China, Japan, Brazil, AUS, Canada, Middle East and Latin America. He also served as VP Head of US Payer Value, Pricing, Strategy & Innovation at UCB where he was responsible for developing teams during a period of expansion and launches. Prior to UCB he held leadership roles in sales, marketing, operations, payor strategy, and market access at Amgen. Mr. Jahr holds a Master of Business Administration degree and a Bachelor of Science degree in Business Administration and Management from University of Montana. Inducement Grant Additionally, Outlook Therapeutics announced that the independent members of its Board of Directors approved the issuance of an option to purchase 800,000 shares of common stock to Mr. Jahr in accordance with Nasdaq Listing Rule 5635(c)(4), as a material inducement to Mr. Jahr's start of employment with Outlook Therapeutics. The option will be issued on July 1, 2025 with an exercise price per share equivalent to the closing price of Outlook Therapeutics' common stock on the date of grant. The option will vest over four years, with 25% of the shares subject to the option vesting on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the three years thereafter, subject to Mr. Jahr's continuous service through the applicable vesting date. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'continue,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' or 'would' the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, expectations concerning the therapeutic potential of ONS-5010/LYTENAVA™ as a treatment of wet AMD, Outlook Therapeutics' commercialization strategy, the market opportunity for ONS-5010/LYTENAVA™, expectations concerning decisions of regulatory bodies and the timing thereof, ONS-5010/LYTENAVA™'s potential as the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal indications, including wet AMD, in the United States and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, the sufficiency of Outlook Therapeutics' resources, unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions (including the long-term impacts of ongoing overseas conflicts, tariffs and trade tensions, fluctuations in inflation and interest rates and other economic uncertainty), as well as those risks detailed in Outlook Therapeutics' filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, the Quarterly Report on Form 10-Q for fiscal quarter ended March 31, 2025 and future quarterly reports Outlook Therapeutics files with the SEC. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. Investor Inquiries: Jenene Thomas Chief Executive Officer JTC Team, LLC T: 908.824.0775 [email protected]
CNET
an hour ago
- CNET
Should You Throw Out Expired Vitamins? Why That Date Might Not Matter as Much as You Think
Who hasn't been digging through a medicine cabinet only to find that their vitamins and other supplements have passed their expiration dates. It happens. Your gut reaction is to chuck them in the trash. After all, we do the same for food after we see that it's out of date, so why not supplements? The reality is that vitamins don't necessarily "go bad" the same way that food does. In fact, understanding what that date on the label actually means is a bit more complicated. In this guide we'll break down what happens to supplements over time and whether you should use them after the date on the bottle passes. Do vitamins expire? Your vitamin bottles most likely have a date on them, but that's not technically an expiration date. That's because your vitamins don't expire in the way that you may think. Because vitamins don't become unsafe when they "expire," the Food and Drug Administration doesn't even require a date to be put on the bottles. Most manufacturers still do, though, because there is a point when vitamins lose potency. This means that your vitamins and minerals may not be providing the full nutritional value you expect if they're past their shelf life. Depending on your vitamins and supplements and what form they're in, they lose potency at different rates. Tablets and capsules tend to stay potent for longer than something like a chewable gummy vitamin. The best way to store your vitamins is in a cool, dry place. Two of the worst places -- and two of the most common -- are in the bathroom and the kitchen. Both of these rooms run warm and damp, which can make your vitamins break down faster. Putting your vitamins in a closet or in a spot in your bedroom that's not getting direct sunlight can help prolong their potency. How expired is 'too expired' for vitamins? Ayrat Gabdrakhmanov/iStock/Getty Images Though vitamins won't expire and become unsafe, they will lose potency, which means they're not doing you any good. Manufacturers put the dates on the bottle that signifies when the vitamins hit that point, so if you're past the "best by" date on a bottle, go ahead and toss them because, while they won't make you sick, they also won't help you. Though it's not common, vitamins can become moldy or smelly, especially if they're not stored properly. If your vitamins are in this condition, throw them out immediately and get a new bottle. This is a situation where your vitamins can be unsafe to consume because of whatever contamination is happening with them. There are currently no documented cases of "expired" vitamins becoming toxic or dangerous to people. Expired vitamins are really just a waste of time and not much else. How long can you use vitamins after expiration date? Although taking vitamins past their expiration date is OK, it will depend on how well you've stored them and if they have been opened. Other factors to consider are the type of vitamin and what it's made of. For example, vitamins in gummy form tend to degrade faster than those in tablet or capsule form because they are more prone to absorbing moisture. A good rule of thumb is that if mold is present, the smell is off or the consistency has changed, throw it out. How to dispose of expired vitamins After you've determined your vitamins are past the point of no return, it's important to get rid of them safely. Simply throwing them in the trash can be a risk, because children or even pets could end up getting a hold of them. And while you might be tempted to flush them down the toilet, that's not a good idea because old vitamins can still potentially contaminate the water. The FDA recommends dumping the vitamins out of the bottle and into a plastic bag and mixing them with an "undesirable substance" like coffee grounds or cat litter. Seal the mixture in the bag and put that bag into your trash. You can also take your vitamins to a drug take-back center in your community if you have one. While these are more commonly used for prescription drugs, you can also dispose of your vitamins so they can be handled safely. The bottomWhile your vitamins won't technically expire, they will become useless after a period of time. Pay attention to the dates the manufacturers put on bottles so you know when your vitamins and supplements will stop working for you. As long as you're storing them properly, they will last as long as they're meant to -- and contribute to your overall health.
Yahoo
2 hours ago
- Yahoo
How Many Espresso Shots Is Too Many In One Day?
Coffee culture is strong in the United States, encompassing a range of options from iced coffees to frappés, cappuccinos, and espressos. You usually get most coffee drinks in a pretty decent-sized cup (around 8 ounces), whether you get it from a shop or make it at home in your favorite beginner-friendly machine. The espresso is different, though, as a standard serving of this drink is roughly one ounce, which lets you know that the espresso might be small, but it's mighty. A single shot of espresso contains around 29 to 100 milligrams of caffeine (75mg is the average), depending on the bean, roast, and brewing method. That means if you're sipping on a double shot, you're consuming roughly 60 to 150 mg of caffeine in one go. According to the FDA, the recommended safe limit for daily caffeine intake is 400 milligrams for healthy adults. That puts the cap at about five or six espresso shots per day, and that's only if you're not getting caffeine from any other source. The tricky part here is that caffeine tolerance isn't a one-size-fits-all number. Some people are more sensitive due to genetics, body size, or other health conditions, and you want to keep that in mind when you're trying to figure out the magic number for yourself. Drinking more than your body can handle could lead to symptoms like insomnia, anxiety, jitters, increased heart rate, and even digestive issues. On the flip side, others may build up tolerance over time, meaning they need more caffeine to feel the same boost, but that also increases dependency. So, how much caffeine is okay? Listen to your body and give your real-life experience priority over the math — even if you're technically under the limit. Read more: Bartenders Chime In On 12 Drink Orders That Ring Alarm Bells Caffeine stimulates your central nervous system, and espresso delivers it fast because it's highly concentrated. Once you drink it, caffeine blocks adenosine, which is the brain chemical responsible for making you feel sleepy. This results in heightened alertness and sometimes an improved sense of focus or mood, which is why people reach for espresso to power through mornings or to get through the midday slump when things are dragging. Here's how caffeine affects you depending on several varying factors. Your genetics play a big role, and some people metabolize caffeine quickly, while others are slow metabolizers. That's why two people can drink the same number of espresso shots and have totally different reactions — one feels fine, while the other is battling heart palpitations. Your age, medications, liver function, and even hormonal cycles can change how long caffeine stays in your body. Typically, caffeine has a half-life of 3 to 7 hours (with an average of 5 hours), but for some individuals, it can linger even longer. It's also worth noting that since caffeine affects sleep quality, consider the fact that your caffeine window might be too wide if you're still struggling to sleep at night. Even drinking it a few hours before bedtime might be cutting it too close. Keeping your last shot before 2 or 3 p.m. is a good rule of thumb for most people. If you love espresso but don't want to overdo it, a few smart habits can keep your daily intake balanced. First, spread your shots out; instead of drinking two or three all at once, try spacing them throughout the day. This reduces the risk of a caffeine crash and helps avoid the shaky, anxious feeling that sometimes comes from one big jolt. Also, track all your caffeine sources, and not just the espressos. If you're drinking tea, soda, or your favorite energy drink as well, your total caffeine intake can sneak up fast. Even some medications and supplements contain hidden caffeine, so be sure to check those as well. Try to stay under 400 mg per day, or even less if you're sensitive. It's also a good idea to take occasional breaks from caffeine. If you find yourself needing multiple shots just to feel normal, you might be building a tolerance and an unhealthy dependence. Cutting back gradually for a few days can help reset your baseline, and you can also explore decaf or half-caf espresso blends for your second or third coffee of the day. Espresso should be enjoyable — not something that causes crashes, anxiety, or restless nights. For more food and drink goodness, join The Takeout's newsletter. Get taste tests, food & drink news, deals from your favorite chains, recipes, cooking tips, and more! Read the original article on The Takeout.
